CIK 0001832168
LBPH Longboard Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Dec 2, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at Longboard Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Randall Kaye CMO sell | $984k 16,667 shares | -48% | - |
Transactions
The last 52 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Paul J Sekhri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,461 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Phillip M Schneider director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,461 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | UTender of shares Common Stock | -30,554 | $60.00 | $1.8M | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Vincent Aurentz director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -139,380 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Casey Lynch director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | UTender of shares Common Stock | -363,740 | $60.00 | $22M | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Corinne Le Goff director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -255,377 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Paul J Sekhri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Phillip M Schneider director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -90,000 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Casey Lynch director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,428 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Vincent Aurentz director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -7,214 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Corinne Le Goff director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -13,397 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -175,946 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -96,300 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Vincent Aurentz director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Phillip M Schneider director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Paul J Sekhri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -119,700 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Corinne Le Goff director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -192,783 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Casey Lynch director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,367 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -107,560 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Paul J Sekhri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Casey Lynch director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -90,580 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -325,850 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Vincent Aurentz director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Phillip M Schneider director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Corinne Le Goff director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Casey Lynch director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Restricted Stock Unitderivative | -15,090 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | DDisposition to issuer Employee Stock Option (right to buy)derivative | -332,134 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Corinne Le Goff director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | DDisposition to issuer Restricted Stock Unitderivative | -17,920 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Vincent Aurentz director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Kevin Robert Lind President and CEO | DDisposition to issuer Restricted Stock Unitderivative | -22,000 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Randall Kaye Executive Vice President & CMO | DDisposition to issuer Restricted Stock Unitderivative | -9,500 | - | - | 0 | Dec 2, 2024 |
| Dec 2, 2024 | Brandi Roberts Executive VP and CFO | DDisposition to issuer Restricted Stock Unitderivative | -7,900 | - | - | 0 | Dec 2, 2024 |
| Nov 19, 2024 | Randall Kaye CMO | MOption exercise Common Stock | +30,554 | $6.00 | $183k | 48,474 | Nov 19, 2024 |
| Nov 19, 2024 | Randall Kaye CMO | MOption exercise Stock Option (Right to Buy)derivative | -30,554 | $0.00 | $0 | 175,946 | Nov 19, 2024 |
| Nov 13, 2024 | Kevin Robert Lind CEO | MOption exercise Common Stock | +12,808 | $3.12 | $40k | 443,740 | Nov 13, 2024 |
| Nov 13, 2024 | Kevin Robert Lind CEO | GGift Common Stock | -80,000 | $0.00 | $0 | 363,740 | Nov 13, 2024 |
| Nov 13, 2024 | Kevin Robert Lind CEO | MOption exercise Stock Option (Right to Buy)derivative | -12,808 | $0.00 | $0 | 255,377 | Nov 13, 2024 |
| Oct 25, 2024 | Randall Kaye CMO | AGrant or award Retention Restricted Stock Unitsderivative | +9,500 | $0.00 | $0 | 9,500 | Oct 29, 2024 |
| Oct 25, 2024 | Kevin Robert Lind CEO | AGrant or award Retention Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 22,000 | Oct 29, 2024 |
| Oct 25, 2024 | Brandi Roberts CFO | AGrant or award Retention Restricted Stock Unitsderivative | +7,900 | $0.00 | $0 | 7,900 | Oct 29, 2024 |
| Oct 15, 2024 | Randall Kaye CMO | MOption exercise Common Stock10b5-1 | +16,667 | $4.35 | $73k | 34,587 | Oct 16, 2024 |
| Oct 15, 2024 | Randall Kaye CMO | SOpen-market sale Common Stock10b5-1 | -16,667 | $59.04 | $984k | 17,920 | Oct 16, 2024 |
| Oct 15, 2024 | Randall Kaye CMO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,667 | $0.00 | $0 | 96,300 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Vincent Aurentzdirector
- Randall KayeExecutive Vice President & CMO
- Corinne Le Goffdirector, officer
- Kevin Robert LindPresident and CEO
- Casey Lynchdirector
- Brandi RobertsExecutive VP and CFO
- Phillip M Schneiderdirector
- Paul J Sekhridirector, ceo, chair, officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.